| Dr William J Berglind, MD | |
|
301 Fisher Street, Kafb, Biloxi, MS 39534 | |
| (228) 376-0425 | |
| (228) 376-0020 |
| Full Name | Dr William J Berglind |
|---|---|
| Gender | Male |
| Speciality | General Surgery |
| Experience | 12 Years |
| Location | 301 Fisher Street, Kafb, Biloxi, Mississippi |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1518228741 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208600000X | Surgery | MD34721 (South Carolina) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Garden Park Medical Center | Gulfport, MS | Hospital |
| Memorial Hospital At Gulfport | Gulfport, MS | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Singing River Gulfport | 5294154829 | 106 |
News Archive
Teva Pharmaceutical Industries Ltd. today announced results from the Phase II ALSTAR trial. The trial was designed to assess efficacy, safety and tolerability of Talampanel (a selective AMPA antagonist) in reducing disease-related functional deterioration in Amyotrophic Lateral Sclerosis patients.
News outlets detail the tone of this week's debate in the House of Representatives. They also parse some of the specific dynamics of the arguments in play.
Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, announced that additional data will be presented from its IMPRESS (The Investigation for Maximal Peyronie's Reduction Efficacy and Safety Studies) trials, the phase III studies that assessed XIAFLEX (collagenase clostridium histolyticum or CCH), a novel, in-office, first-in-class biologic therapy for the potential treatment of Peyronie's disease (PD).
Whether we're listening to Bach or the blues, our brains are wired to make music-color connections depending on how the melodies make us feel, according to new research from the University of California, Berkeley.
Two researchers from the University of Santiago de Compostela have studied the relationship between teenagers' goals and antisocial behaviour. The results show that the principal goal of young people is to finish their studies and leave home. The most antisocial among them place greater importance on popularity with others.
› Verified 7 days ago
| Entity Name | Singing River Health System |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1083893937 PECOS PAC ID: 3870405194 Enrollment ID: O20031104000435 |
News Archive
Teva Pharmaceutical Industries Ltd. today announced results from the Phase II ALSTAR trial. The trial was designed to assess efficacy, safety and tolerability of Talampanel (a selective AMPA antagonist) in reducing disease-related functional deterioration in Amyotrophic Lateral Sclerosis patients.
News outlets detail the tone of this week's debate in the House of Representatives. They also parse some of the specific dynamics of the arguments in play.
Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, announced that additional data will be presented from its IMPRESS (The Investigation for Maximal Peyronie's Reduction Efficacy and Safety Studies) trials, the phase III studies that assessed XIAFLEX (collagenase clostridium histolyticum or CCH), a novel, in-office, first-in-class biologic therapy for the potential treatment of Peyronie's disease (PD).
Whether we're listening to Bach or the blues, our brains are wired to make music-color connections depending on how the melodies make us feel, according to new research from the University of California, Berkeley.
Two researchers from the University of Santiago de Compostela have studied the relationship between teenagers' goals and antisocial behaviour. The results show that the principal goal of young people is to finish their studies and leave home. The most antisocial among them place greater importance on popularity with others.
› Verified 7 days ago
| Entity Name | Vicksburg Healthcare Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629084058 PECOS PAC ID: 4688575129 Enrollment ID: O20040213000299 |
News Archive
Teva Pharmaceutical Industries Ltd. today announced results from the Phase II ALSTAR trial. The trial was designed to assess efficacy, safety and tolerability of Talampanel (a selective AMPA antagonist) in reducing disease-related functional deterioration in Amyotrophic Lateral Sclerosis patients.
News outlets detail the tone of this week's debate in the House of Representatives. They also parse some of the specific dynamics of the arguments in play.
Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, announced that additional data will be presented from its IMPRESS (The Investigation for Maximal Peyronie's Reduction Efficacy and Safety Studies) trials, the phase III studies that assessed XIAFLEX (collagenase clostridium histolyticum or CCH), a novel, in-office, first-in-class biologic therapy for the potential treatment of Peyronie's disease (PD).
Whether we're listening to Bach or the blues, our brains are wired to make music-color connections depending on how the melodies make us feel, according to new research from the University of California, Berkeley.
Two researchers from the University of Santiago de Compostela have studied the relationship between teenagers' goals and antisocial behaviour. The results show that the principal goal of young people is to finish their studies and leave home. The most antisocial among them place greater importance on popularity with others.
› Verified 7 days ago
| Entity Name | Singing River Gulfport |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1861010159 PECOS PAC ID: 5294154829 Enrollment ID: O20201001001497 |
News Archive
Teva Pharmaceutical Industries Ltd. today announced results from the Phase II ALSTAR trial. The trial was designed to assess efficacy, safety and tolerability of Talampanel (a selective AMPA antagonist) in reducing disease-related functional deterioration in Amyotrophic Lateral Sclerosis patients.
News outlets detail the tone of this week's debate in the House of Representatives. They also parse some of the specific dynamics of the arguments in play.
Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, announced that additional data will be presented from its IMPRESS (The Investigation for Maximal Peyronie's Reduction Efficacy and Safety Studies) trials, the phase III studies that assessed XIAFLEX (collagenase clostridium histolyticum or CCH), a novel, in-office, first-in-class biologic therapy for the potential treatment of Peyronie's disease (PD).
Whether we're listening to Bach or the blues, our brains are wired to make music-color connections depending on how the melodies make us feel, according to new research from the University of California, Berkeley.
Two researchers from the University of Santiago de Compostela have studied the relationship between teenagers' goals and antisocial behaviour. The results show that the principal goal of young people is to finish their studies and leave home. The most antisocial among them place greater importance on popularity with others.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr William J Berglind, MD 301 Fisher St Ste 5a207, Biloxi, MS 39534-2508 Ph: (228) 376-3059 | Dr William J Berglind, MD 301 Fisher Street, Kafb, Biloxi, MS 39534 Ph: (228) 376-0425 |
News Archive
Teva Pharmaceutical Industries Ltd. today announced results from the Phase II ALSTAR trial. The trial was designed to assess efficacy, safety and tolerability of Talampanel (a selective AMPA antagonist) in reducing disease-related functional deterioration in Amyotrophic Lateral Sclerosis patients.
News outlets detail the tone of this week's debate in the House of Representatives. They also parse some of the specific dynamics of the arguments in play.
Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, announced that additional data will be presented from its IMPRESS (The Investigation for Maximal Peyronie's Reduction Efficacy and Safety Studies) trials, the phase III studies that assessed XIAFLEX (collagenase clostridium histolyticum or CCH), a novel, in-office, first-in-class biologic therapy for the potential treatment of Peyronie's disease (PD).
Whether we're listening to Bach or the blues, our brains are wired to make music-color connections depending on how the melodies make us feel, according to new research from the University of California, Berkeley.
Two researchers from the University of Santiago de Compostela have studied the relationship between teenagers' goals and antisocial behaviour. The results show that the principal goal of young people is to finish their studies and leave home. The most antisocial among them place greater importance on popularity with others.
› Verified 7 days ago
Hope Burkett, D.O. Surgery Medicare: Accepting Medicare Assignments Practice Location: 147 Reynoir Street 201, Biloxi, MS 39530 Phone: 228-436-1348 | |
Mark Belknap, MD Surgery Medicare: Not Enrolled in Medicare Practice Location: 400 Veterans Ave, Dr. Belknap 112, Biloxi, MS 39531 Phone: 903-926-2071 | |
Dr. Joshua A Tyler, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 147 Reynoir St Ste 200, Biloxi, MS 39530 Phone: 228-436-1273 Fax: 228-435-3211 | |
Luis Michael Diaz, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 970 Tommy Munro Dr Ste B, Biloxi, MS 39532 Phone: 228-396-2663 Fax: 228-396-2664 | |
Dr. Robert L Brunston Jr., M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 1720a Medical Park Dr, Suite 180, Biloxi, MS 39532 Phone: 228-396-1735 Fax: 228-396-1737 | |
Dr. Kenneth Simon, M.D. Surgery Medicare: Not Enrolled in Medicare Practice Location: 400 Veterans Ave, Biloxi, MS 39531 Phone: 228-523-5000 |